Table 1 Baseline characteristics of participates in the two groups
Characteristics | DM (n = 36) | Non-DM (n = 62) | P-value |
|---|---|---|---|
Age, y | 69.6 ± 10.3 | 70.0 ± 11.5 | 0.389 |
Male | 30 (83.3) | 52 (83.9) | 0.945 |
BMI, kg/m2 | 24.4 ± 3.8 | 23.1 ± 2.7 | 0.038 |
Systolic BP, mmHg | 141.9 ± 36.6 | 132.8 ± 19.8 | 0.287 |
Diastolic BP, mmHg | 81.6 ± 12.2 | 79.2 ± 8.3 | 0.447 |
Hypertension | 26 (72.2) | 36 (58.1) | 0.161 |
Dyslipidemia | 9 (25) | 10 (16.1) | 0.284 |
Current smoking | 11 (30.6) | 21 (33.9) | 0.736 |
CVD | 8 (22.2) | 7 (11.3) | 0.147 |
CAD family history | 4 (11.1) | 5 (8.1) | 0.888 |
Chest pain | 22 (61.1) | 42 (67.7) | 0.506 |
Anti-diabetic treatment | |||
 Insulin | 9 (25.0) | – | – |
 Metformin | 13 (36.1) | – | – |
 Sulfonylurea | 5 (13.9) | – | – |
 α-Glucosidase inhibitor | 14 (38.9) | – | – |
 Non-drug | 2 (5.5) | – | – |
Statins at discharge | 29 (80.6) | 47 (75.8) | 0.120 |
Clopidogrel/ticlopidine at discharge | 36 (100) | 62 (100) | – |
Inter-scan period, y | 1.8 (1–3.5) | 1 (0.5–2.5) | 0.171 |
No. of stented vessel/patients | 1 (1–2) | 1 (1–2) | 0.235 |
No. of stented lesions/patients | 2 (1–3.75) | 2 (1–2.25) | 0.235 |
Number of stented segments | |||
 1 | 15 (41.7) | 30 (48.4) | 0.520 |
 2 | 8 (22.2) | 17 (27.4) | 0.569 |
 3 | 4 (11.1) | 6 (9.7) | 1 |
 ≥ 4 | 9 (25) | 9 (14.5) | 0.196 |
Number of stented vessels | |||
 1 | 22 (61.6) | 44 (71.0) | 0.316 |
 2 | 9 (25) | 15 (24.2) | 0.929 |
 ≥ 3 | 5 (13.9) | 3 (4.8) | 0.139 |
Stent site | |||
 LM | 3 (8.3) | 4 (6.5) | 0.705 |
 LAD | 25 (69.4) | 35 (56.5) | 0.203 |
 RCA | 18 (50) | 24 (38.7) | 0.276 |
 LCx | 10 (27.8) | 17 (27.4) | 0.969 |